Thursday, September 28, 2017

Advocacy Group Provides 19 Petitions For Expanding Safe Access Of Medical Cannabis To Medical Cannabis Advisory Board




LECUA Patients Coalition of New Mexico

Press Release, For Release:
Immediate

Contact:

Thursday, September 28th 2017

Advocacy Group Provides 19 Petitions For Expanding Safe Access Of Medical Cannabis To Medical Cannabis Advisory Board

These 19 Petitions are being provided to the State Department of Health Medical Cannabis Program so the advisory board can review and recommend to the department for approval additional debilitating medical conditions and medical treatments that would benefit from the medical use of cannabis with the Lynn and Erin Compassionate Use Act.

The Governor’s Office has highlighted the importance of such priorities like; Ensuring Transparency and Ethics in Government, and Keeping all New Mexicans Safe. In the Roundhouse, one of the state legislators’ primary functions is to represent the people who elect them, but it is by no means their only function. They help to solve the numerous problems of their constituents, they serve on interim committees and they continually study new ideas for legislation. The Department of Health’s mission is to promote health and wellness, improve health outcomes, and assure safety net services for all people in New Mexico. And the purpose of the Lynn and Erin Compassionate Use Act is to allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments.

In maintaining what Governor Martinez said, about the ‘important responsibility’ of the Medical Cannabis Advisory Board, these are the Petitions being providing for review; as all the Petitions meet the five items as criteria stated in (Part B) for the Duties and responsibilities of the Medical Cannabis Advisory Board.

During the 2017 Regular Legislative Session, state lawmakers made efforts to legislate a number of changes to the state’s Medical Cannabis Program with over 25 different pieces of legislation, one of the bills vetoed by Gov. Susana Martinez, was House Bill-527, on Friday-April 7th 2017 (same day as the medical cannabis advisory board meeting for April), saying she did so in part because she didn’t want to “eliminate an important responsibility” of the Medical Cannabis Advisory Board. Health Secretary Lynn Gallagher, who has the final word on changes to the state Medical Cannabis Program, hasn’t decided whether to accept new conditions and petitions the board recommended yet form the April 2017 meeting.

November 2017 MCAB Petitions
Health Conditions To Add Petitions:
  1. ADD/ADHD And Tourette's Syndrome
  2. All Forms of Arthritis
  3. Cystic Fibrosis
  4. Degenerative Neurological Disorder / Neuroprotective Applications
  5. Diabetes
  6. Dysmenorrhea
  7. Eczema / Psoriasis
  8. Muscular Dystrophy
  9. Polymyalgia Rheumatica
  10. Post-Concussion Syndrome And TBI
  11. All Types Seizures (such as: psychogenic neurologic disorders; Motor Disorders / Motor Development Disorders)
  12. Substance Abuse Disorder(s)

Medical Treatment Petitions:
  1. Medical Treatment; Pediatric Oncology & Medical Cannabis Use for Antiemetic in State Hospitals
  2. Medical Treatment; Medical Cannabis Program Research & Education Established
  3. Medical Treatment; ADA language for Section 8 of LECUA; Medical cannabis registry
  4. Medical Treatment; Medical Cannabis 3 yr registry identification cards.
  5. Medical Treatment; Recognition of nonresident medical cards.
  6. Medical Treatment; Adequate Supply: LNPP Plant Count Increase
  7. Medical Treatment; Increase MCAB membership

Petitions from the April 2017 MCAB meeting, that the LECUA Patients Coalition of New Mexico provided for review and MCAB result below. The November meeting should have the final decision on these Petitions that MCAB has recommended to add in the MCP.

    Petition Action Vote (Y/N)
2017‐012 Add autism as a condition - Recommended to add to MCP 3-0
2017‐013 Add anxiety as a condition - Recommended to add to MCP 3-1
2017‐014 Add depression - Recommended to add to MCP 4-0
2017‐017 Add Dystonia - Recommended to add to MCP 4-0
2017‐018 Add Migraines - Recommended to add to MCP 4-0
2017‐019 Add Rheumatoid Arthritis - Recommended to expand terms 4-0
2017‐020 Sleep Disorders - Recommended to add to MCP 4-0
2017‐022 Patient Run Collectives - Recommended to add to MCP 4-0
2017-005 Change/increase possession limit to 16 oz - Recommended to add to MCP 4-0
2017-009 Removal of Max THC Content - Recommended Removal of Cap   4-0
2017‐015 Add Concussions, CTE and TBI as a condition was Tabled in April
2017‐021 Add Substance Abuse Disorder as a condition was Tabled in April


This is the best way to accurately review them. Everything that is provided in the printed format is exactly the same on the Petitions website as well. The website was created to provide; the Medical Cannabis Advisory Board members, Secretary Gallagher, Medical Cannabis Program office officials, and the community- the easiest access at viewing all the Petitions. As all the petitions have resources within them, as embedded web links going to additional research and science for the petition it is in, along with the references cited.  

The LECUA Patients Coalition of New Mexico is the only patient led group in the State with a primary focus on medical cannabis, that operates in full compliance of the Act, providing patient-community advocacy, and the only group that has no outside financial influences from program producers or ancillary businesses in the medical cannabis program.
The primary focus is on Medical Cannabis, LECUA Patients Coalition Of New Mexico is solely focused on expanding safe access to medical cannabis in New Mexico.
This means that LECUA Patients Coalition Of New Mexico position does support legalization of cannabis for nonmedical therapeutic purposes or on related issues, such as incarceration or sentencing standards for recreational drug use; this support will be to provide advocacy for policy writing that first & foremost protects and improves the spirit and intent of the LECUA, 2007, protects and improves the Medical Cannabis Program in said legislation, and  improves the State Department of Health Medical Cannabis Rules & Regulations.

Petitions Authored & Organized By Jason Barker
- Medical Cannabis Patient & Organizer with the
LECUA Patient’s Coalition Of New Mexico
Free-lance writer for: www.cannabisnewsjournal.co

Americans For Safe Access - Member
American Cannabis Nurses Association - Member
LECUA Patient’s Coalition Of New Mexico - Founder/Organizer
Medical Cannabis Patient in New Mexico

"The American Medical Association has no objection to any reasonable regulation of the medicinal use of cannabis and its preparations and derivatives. It does pretest, however, against being called upon to pay a special tax, to use special order forms in order to procure the drug, to keep special records concerning its professional use and to make special returns to the Treasury Department officials, as a condition precedent to the use of cannabis in the practice of medicine."                     
~Wm. C. Woodward, Legislative Counsel - 11:37 AM Monday, July 12, 1937

Acknowledgments: Whoopi and Maya, Americans For Safe Access, American Cannabis Nurses Association President- Carey Clark, Cannabis News Journal, Buen Salud & Dr. Peter Smith, CG Corrigan, and R. Greenleaf.


download.png

Wednesday, September 27, 2017

Medical Cannabis Advisory Board Petitions Provided for the November 3rd 2017 Meeting

Medical Cannabis Advisory Board Petitions Provided for the November 3rd 2017 Meeting
Health Conditions To Add Petitions:
  1. ADD/ADHD And Tourette's Syndrome
  2. All Forms of Arthritis
  3. Cystic Fibrosis
  4. Degenerative Neurological Disorder / Neuroprotective Applications
  5. Diabetes
  6. Dysmenorrhea
  7. Eczema / Psoriasis
  8. Muscular Dystrophy
  9. Polymyalgia Rheumatica
  10. Post-Concussion Syndrome And TBI
  11. All Types Seizures (such as: psychogenic neurologic disorders; Motor Disorders / Motor Development Disorders)
  12. Substance Abuse Disorder(s)
  13. Veterans Status



Medical Cannabis Advisory Board Petitions Provided for the November 3rd 2017 Meeting
Medical Treatment Petitions:
  1. Medical Treatment; Pediatric Oncology & Medical Cannabis Use for Antiemetic in State Hospitals
  2. Medical Treatment; Medical Cannabis Program Research & Education Established
  3. Medical Treatment; ADA language for Section 8 of LECUA; Medical cannabis registry
  4. Medical Treatment; Medical Cannabis 3 yr registry identification cards.
  5. Medical Treatment; Recognition of nonresident medical cards.
  6. Medical Treatment; Adequate Supply: LNPP Plant Count Increase
  7. Medical Treatment; Increase MCAB membership

 All the Nov. Petitions also had a Preface and Information Page for them; in addition to information regarding ‘Medical Necessity’ for program expansion.  




These are the Petitions from the April 2017 MCAB meeting. The November meeting should have the final decision on these Petitions that MCAB has recommended to add in the MCP.

    Petition Action Vote (Y/N)
2017‐012 Add autism as a condition - Recommended to add to MCP 3-0
2017‐013 Add anxiety as a condition - Recommended to add to MCP 3-1
2017‐014 Add depression - Recommended to add to MCP 4-0
2017‐017 Add Dystonia - Recommended to add to MCP 4-0
2017‐018 Add Migraines - Recommended to add to MCP 4-0
2017‐019 Add Rheumatoid Arthritis - Recommended to expand terms 4-0
2017‐020 Sleep Disorders - Recommended to add to MCP 4-0
2017‐022 Patient Run Collectives - Recommended to add to MCP 4-0
2017-005 Change/increase possession limit to 16 oz - Recommended to add to MCP 4-0
2017-009 Removal of Max THC Content - Recommended Removal of Cap   4-0



Tuesday, September 19, 2017

Study Finds Medical Cannabis May Reduce Use Of Dangerous Prescription Drugs

A Medical Cannabis Cure For The Opioid Epidemic
Medical Cannabis
The United States is in the midst of a major drug epidemic. Stories continue to roll in daily about the lives claimed by prescription and non-prescription drug overdoses. The numbers are staggering. Opioids alone (including prescription pain killers and street heroin) killed more than 33,000 people in 2015, 90+ Americans every single day, and more than any year on record according to the Center for Disease Control (CDC). From 2000 to 2015, half a million people died from prescription drug overdoses.
Opioids
The opioid epidemic is the leading preventable form of death in the United States.
“The potential for addiction and health risks associated with using multiple scheduled drugs places additional direct monetary and health costs on patients and healthcare systems due to an increased number of side effects, risky drug interactions, dependency, and overdose” stated University of New Mexico researchers Jacob Miguel Vigil and Sarah See Stith, of a new study titled, Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions, which will be soon released in an upcoming issue of the Journal of American Medical Directors Association.
The study resulted from insights provided by co-investigator Dr. Anthony Reeve, a pain specialist from the Industrial Rehabilitation Pain Clinics, Albuquerque, N.M. and also one of the first physicians to authorize the use of cannabis for patients with chronic pain in the state of New Mexico.
Reeve observed a number of his patients coming back to see him, not only less frequently after enrolling in the New Mexico Medical Cannabis Program (MCP), but anecdotally, they would often claim that they were not only reducing their pain medications, but other types of prescription medications as well.
In their historical cohort study the researchers compared individuals that enrolled in the medical cannabis program to individuals with a similar diagnosis that chose not to enroll in the medical cannabis program but were offered the same authorization, to measure the effect of enrollment in a state-authorized United States’ MCP on Scheduled II-V drug prescription patterns.
Sarah See Stith and Jacob Vigil
UNM Economics Assistant Professor Sarah See Stith and Psychology Associate Professor Jacob Vigil.
They compared 83 chronic pain patients, who enrolled in the New Mexico Medical Cannabis Program during a five+ year period from April 2010 to October 2015, to 42 non-enrolled patients over a 24 month period (starting 6 months prior to enrollment for the MCP patients) using the Prescription Monitoring Program.
Using outcome variables including baseline levels and pre- and post-enrollment monthly trends in the numbers of drug prescriptions, distinct drug classes, dates prescription drugs were filled, and prescribing providers, the researchers found that 28 cannabis program enrollees (34 percent) and one comparison group patient (2 percent) ceased the use of all scheduled prescription medications by the last six months of the observation period.
Age and gender-adjusted regressions show that, although no statistically significant differences existed in pre-enrollment levels and trends, the post-enrollment trend among MCP patients is statistically significantly negative for all four measures of scheduled drug medication usage, while the post-enrollment trend is zero among the comparison group. The cannabis program enrollees showed statistically significantly lower levels across all four measures in comparison to the non-enrollees by 10 months post-enrollment. The researchers hypothesize that legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations.
“Our current opioid epidemic is the leading preventable form of death in the United States, killing more people than car accidents and gun violence,” said Vigil, the senior author and Associate Professor in the Department of Psychology. “No one has ever died from smoking too much cannabis. Therefore, the relative safety and efficacy of using cannabis in comparison to that of the other scheduled medications should be taken by the health providers and legislators, and may very well to have been considered by the patients in our study.”
Medical Cannabis

The authors state that increased patient access to MCPs could impact prescription drug activity in numerous ways. “Potentially, MCPs might drive increased prescribing of medications as a result of side effects of cannabis use, including agitation or somnolence. Alternatively, access to cannabis could lead to a reduction in scheduled prescription drug use, if it treats patients’ underlying condition(s) more effectively than scheduled drugs requiring a prescription.”
The researchers are currently employing naturalistic studies to identify how older patients use and are affected by opioids, benzodiazepines, and medical cannabis for treating significant and societally expensive health conditions.
To support this and related research on the safety and effectiveness of Cannabis sativa as a pharmacological agent, you can do so by donating to The University of New Mexico Medical Cannabis Research Fund.
How Medical Cannabis Can Cure the Opioid Epidemic with Dr. Jacob Vigil

This News first broke by By Steve Carr on September 08, 2017 with the UNM Newsroom